Skip to search formSkip to main contentSkip to account menu

grepafloxacin

Known as: (+--)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-, (RS)-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline- 3-carboxylic acid 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Anti-Bacterial AgentsFluoroquinolonesPiperazinesTopoisomerase II Inhibitors
Grepafloxacin:Susc:Pt:Isolate:OrdQn:Gradient strip

Narrower (1)

OPC 17116

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
Medicinal chemistry of hERG optimizations: Highlights and hang-ups.
In recent years, withdrawal of marketed drugs including sertindole, grepafloxacin, and terfenadine owing to prolongation of the… 
Highly Cited
2005
Highly Cited
2005
Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing.
Highly Cited
2002
Highly Cited
2002
Clinical toxicological aspects of fluoroquinolones.
Highly Cited
2002
Highly Cited
2002
Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
The purpose of this study was to clarify the contribution of P-glycoprotein to the bioavailability and intestinal secretion of… 
Highly Cited
2000
Highly Cited
2000
Effects of fluoroquinolones on HERG currents.
Highly Cited
2000
Highly Cited
2000
Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.
days 3‐5 of therapy have indicated a mean prolongation of QTc of 6 ms (� 26 ms) in 9.5% of moxifloxacin-treated patients compared… 
Review
1999
Review
1999
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Highly Cited
1999
Highly Cited
1999
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
The in-vitro activity of grepafloxacin, a new oral fluoroquinolone antibiotic, was compared with those of three other… 
Highly Cited
1997
Highly Cited
1997
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
This analysis was designed to characterize the population pharmacokinetics and pharmacodynamics of oral grepafloxacin (OPC-17,116… 
Review
1988
Review
1988
Safety Overview: Toxicity, Adverse Effects, and Drug Interactions
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)